louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02576262: HPV Integration Testing for Human Papillomavirus-Positive Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cervical Intraepithelial Neoplasia
Cervical Cancer
Lead sponsor: Huazhong University of Science and Technology
Sponsor class: OTHER
First posted: 2015-10-15
Enrollment: 1200
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: participants who visited the gynecologic clinic of hospital for various gynecologic disorders and underwent primary HPV testing were prospectively recruited

Brief summary: Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. the investigators evaluated the potential role of HPV Integration detection in cervical exfoliated cells in HPV-positive women from a clinic-based population.


Eligibility criteria: Inclusion Criteria:

Women aged 30-65 years old visiting the gynecologic clinic of hospital

Exclusion Criteria:

1. Not providing informed consent
2. previously confirmed CIN, cervical cancer, or other malignancies
3. previous therapeutic procedure to cervix
4. pregnancy

Primary outcomes:
measure: Sensitivity and Specificity of the HPV integration screening test with comparison to HPV testing or TCT
timeFrame: 14 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
affiliation: Huazhong University of Science and Technology
name: Ding Ma, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04778943: Oblique Lateral Interbody Fusion Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion
Official title: Oblique Lateral Interbody Fusion Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion for Lumbar Spinal Stenosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lumbar Spinal Stenosis
Keywords: Lumbar spinal stenosis
OLIF
MIS-TLIF
postoperative improvements
Lead sponsor: Tang-Du Hospital
Sponsor class: OTHER
First posted: 2021-03-03
Enrollment: 130
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who were diagnosed with LSS and underwent either MIS-TLIF or OLIF surgery between January 2016 and December 2019.

Brief summary: The investigators will retrospectively study lumbar spinal stenosis patients who underwent OLIF or MIS-TLIF with percutaneous pedicle screw fixation between January 2016 and December 2019.The investigators will measure estimated blood loss, operative time, hospital stay, cost, reoperation, and complication incidence, visual analogue scale (VAS), Oswestry Disability Index (ODI), Japanese Orthopaedic Association (JOA), and Short Form-36 (SF-36) scores, discal and foraminal height, lumbar lordotic angle, and fusion status.The investigators will conduct to evaluate postoperative improvements, complications, and reoperation rates between patients with lumbar spinal stenosis (LSS) undergoing oblique lateral interbody fusion (OLIF) or minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).


Eligibility criteria: Inclusion Criteria:

* LSS due to neurogenic claudication; Central stenosis or lateral stenosis who need surgery; Single-level, low-grade (Meyerding grade 1 or 2) isthmic spondylolisthesis or degenerative spondylolisthesis; and imaging findings consistent with the symptoms of LSS.

Exclusion Criteria:

* trauma, active infection, malignant tumors, spinal deformity, previous lumbar fusion, multi-segment fusion, multi-level, high-grade (Meyerding grade 3 or 4) isthmic spondylolisthesis or degenerative spondylolisthesis.

Primary outcomes:
measure: Oswestry Disability Index (ODI), , and Short Form-36 (SF-36) scores; discal and foraminal height; lumbar lordotic angle; and fusion status.
timeFrame: 2 Years
Secondary outcomes:
measure: Japanese Orthopaedic Association (JOA)
timeFrame: 2 Years
measure: visual analogue scale (VAS)
timeFrame: 2 Years
measure: Short Form-36 (SF-36) scores
timeFrame: 2 Years
measure: Major Complication rate
timeFrame: 2 Years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05109143: Efficacy of Rectal Indomethacin in Prevention of Post-operative Pancreatitis After Pancreaticoduodenectomy
Official title: Efficacy of Rectal Indomethacin in Prevention of Post-operative Pancreatitis After Pancreaticoduodenectomy - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreatoduodenectomy
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2021-11-05
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pancreatico-duodenectomy is one of the commonly performed procedure for periampullary/distal cholangio/head of pancreas carcinoma. Post operative pancreatitis is an emerging concept, recently being studied as one of the most important contributing factor of Post-operative pancreatic fistula, which is one of the major complication of pancreatoduodenectomy. Rectal indomethacin, a type of non-steroidal anti-inflammatory drug, when given in a single dose has been shown to prevent pancreatitis in patients undergoing ERCP. In this study, we will be administering rectal indomethacin at the time of induction of anesthesia to the experimental arm of the study and compare the results in terms of incidence of post-operative pancreatitis in the two groups.


Eligibility criteria: Inclusion Criteria:

* All consenting adults planned to undergo pancreatoduodenectomy,

Exclusion Criteria:

* asthma
* allergic reactions to NSAIDs
* CKD
* internal hemorrhoids
* anti-platelet medications

Primary outcomes:
measure: Post-operative Pancreatitis
timeFrame: first 30 days following pancreatoduodenectomy
Secondary outcomes:
measure: Post-operative Pancreatic Fistula
timeFrame: first 30 days following pancreatoduodenectomy
measure: delayed gastric emptying
timeFrame: First 30 days following pancreatoduodenectomy
measure: intra-abdominal abscess
timeFrame: first 30 days following pancreatoduodenectomy
measure: Length of ICU stay
timeFrame: First 30 days following pancreatoduodenectomy
measure: Length of hospital stay
timeFrame: First 30 days following pancretoduodenectomy
measure: risk factors of post-operative pancreatitis
timeFrame: first 30 days following pancreatoduodenectomy
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver & Biliary Sciences
state: Delhi
Study officials:
affiliation: Institute of Liver & Biliary Sciences
name: Viniyendra Pamecha, FEBS
role: STUDY_DIRECTOR
References:
Clinical trial NCT05950243: COVID-19 Disease & Vaccine Survey in Africa
Official title: COVID-19 Disease & Vaccine Survey in Sub-Saharan Africa
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Vaccine Hesitancy
Keywords: COVID-19
Lead sponsor: Salem Anaesthesia Pain Clinic
Sponsor class: OTHER
First posted: 2023-07-18
Enrollment: 1000
Sex: ALL
Minimum age (years): 9
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Urban population in selected sub-Saharan African town or city

Brief summary: The COVID-19 pandemic is a public health concern; for which the WHO recommends protective measures and vaccination. There is inadequate data on the impact of COVID-19 vaccination and control measures in Africa. This survey is collecting data about people's knowledge, attitude and compliance regarding COVID-19 disease and vaccines.

Detailed description: The coronavirus disease 2019 (COVID-19) pandemic remains a major public health concern. There is inadequate data on the epidemiology of COVID-19 in Africa. There are emerging COVID-19 variants with high transmissibility and morbidity. The World Health Organization (WHO) recommends protective measures and vaccination; for the control of COVID-19. There is inadequate data on the impact of COVID-19 vaccination and control measures in many nations in Africa.

This study is a survey of specific urban populations in sub-Saharan Africa. The anonymized survey is collecting data about people's knowledge and attitude regarding COVID-19 disease or control measures. The survey is also collecting data about people's knowledge, attitude and compliance regarding COVID-19 vaccines. The study uses a validated questionnaire to collect data. The study aims to inform and improve COVID-19 management or control in Africa.

Eligibility criteria: Inclusion Criteria:

* urban population in Africa
* people in sub-Saharan Africa town

Exclusion Criteria:

* rural population
* people outside sub-Saharan Africa

Primary outcomes:
measure: Percentage of people who know about COVID-19 prevention
timeFrame: 6 months
measure: Percentage of people who received COVID-19 vaccination
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Surrey
country: Canada
facility: Salem Anaesthesia Pain Clinic
state: British Columbia
Study officials:
affiliation: Salem Anaesthesia Pain Clinic
name: Olu Bamgbade, MD,FRCPC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00083343: Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Official title: A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults With Invasive Candida Infections (Excluding Patients With Candidemia as the Sole Site of Infection)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Candidiasis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2004-05-24
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs). The study will not enroll patients whose only site of Candida infection was the bloodstream. Patients that fulfill all study entry criteria will receive a single daily dose of caspofungin. Caspofungin, an intravenous echinocandin antifungal agent, is already approved for the treatment of invasive candidiasis. The dosage strength and duration of caspofungin will be individualized for each patient based on disease, severity of disease and extent of infection.


Eligibility criteria: Inclusion Criteria:

* All patients must have at least 1 positive culture for Candida species obtained from an otherwise sterile, non-blood body site within 96 hours of the study entry.
* The patient must also have clinical evidence of Candida infection (e.g., oral temperature \>100 degrees Fahrenheit, signs of inflammation from infected site, systolic blood pressure \<90) within 96 hours of study entry.
* The patient must be at least 18 years old, and if a woman of child bearing potential, must have a negative serum or urine pregnancy test sensitive to 25 IU HCG prior to enrollment.

Exclusion Criteria:

* Patients whose only site of Candida infection was the bloodstream.

Primary outcomes:
measure: Favorable overall response rate
Secondary outcomes:
measure: Favorable overall response rate on Day 10 of caspofungin therapy
measure: Occurance of relapse during the 12 week follow-up period following the completion of all antifungal therapy
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Petrovic J, Ngai A, Bradshaw S, Williams-Diaz A, Taylor A, Sable C, Vuocolo S, Kartsonis N. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc. 2007 Dec;39(10):3117-20. doi: 10.1016/j.transproceed.2007.10.003.
Clinical trial NCT02289638: Effectiveness of Child Intubation
Official title: First Comparison of the /Intubrite VideoLaryngoscope System Versus the Miller Laryngoscope for Intubations by Non-anaesthetists: a Manikin Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrest
Keywords: intubation
Lead sponsor: International Institute of Rescue Research and Education
Sponsor class: OTHER
First posted: 2014-11-13
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: We hypothesized that the Intubrite Video Laryngoscope System VLS 6600 is beneficial for intubation of pediatric manikins while performing CPR. In the current study, we compared effectiveness of the Intubrite and MIL laryngoscopes in child resuscitation with and without CC.


Eligibility criteria: Inclusion Criteria:

* Give voluntary consent to participate in the study
* minimum 1 year of work experience in emergency medicine
* experienced emergency medical personnel (physicians, nurses, paramedics)

Exclusion Criteria:

* Not meet the above criteria
* Wrist or Low back diseases

Primary outcomes:
measure: Success of intubation
timeFrame: 1 day
Secondary outcomes:
measure: Intubation time
timeFrame: 1 day
measure: POGO score
timeFrame: 1 day
measure: Cormack-Lehane grading
timeFrame: 1 day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: International Institute of Rescue Research and Education
state: Masovia
Study officials:
affiliation: Institute of Cardiology
name: Lukasz Szarpak
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04051138: The Effect of VOXX/eSmartr High Performance Technology on Sports Vision Ability
Official title: The Effect of VOXX/eSmartr High Performance Technology on Sports Vision Ability
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vision, Binocular
Sports Medicine
Lead sponsor: ChampionsEdge, LLC
Sponsor class: INDUSTRY
First posted: 2019-08-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: randomized, double blind, prospective
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study is designed to compare the effect of Voxx/eSmartr technology on common measures of sports vision performance including (Hand-Eye Coordination/Reaction time, visual concentration and basic visual functions of size detection and contrast sensitivity). The study will be a randomized, prospective, double-blind design in order to determine the effect of this technology on a subject's sports vision ability.


Eligibility criteria: Inclusion Criteria.

* Female or Male age 18-45 years of age
* Exercises at least once a week by self-report
* Physically able to complete the HEC/RT test (e.g. no shoulder or arm discomfort or limitation

Exclusion Criteria.

* Member of a vulnerable population
* Visual or physical condition which precludes performing the physical or visual testing (e.g. strabismus, double vision, shoulder or arm pain or injury)
* Previous training in hand-eye coordination/reaction time or visual concentration
* History of double vision or strabismus
* Insufficient vision to drive an automobile in NY State

Primary outcomes:
measure: CoreScore
timeFrame: 1 day
Secondary outcomes:
measure: Hand-Eye Coordination/Reaction Time
timeFrame: 1 day
measure: Neurotracker score
timeFrame: 1 day
Other outcomes:
Locations:
city: New York
country: United States
facility: SportsVisionNYC
state: New York
Study officials:
affiliation: ChampionsEdge, LLC
name: Daniel M Laby, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02025738: Perioperative Management of Patients With Cardiac Implantable Electronic Devices
Official title: Perioperative MAnaGement of patieNts With Cardiac Implantable Electronic Devices: Randomized Controlled Pilot Trial (MAGNET Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: CARDIAC PACEMAKERS DEFIBRILLATOR ELECTROMAGNETIC
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2014-01-01
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Data on the perioperative management of patients cardiac implantable electronic devices (CIEDs) is limited and published guidelines rely mainly on the experience of the cardiologists and anesthesiologists who manage these patients. Depending on the device type and patient's dependency, these guidelines recommend the intraoperative magnet use, reprogramming of devices or no action. Magnet placement on a CIED (very simple and applicable method) has become the standard approach in many centers, while CIED reprograming by trained personnel is required in most centers. Therefore, our objective is to compare in a prospective randomized clinical trial the safety of intraoperative magnet use vs. CIEDS reprogramming vs. no intervention (in the appropriate subjects)


Eligibility criteria: Inclusion Criteria:

* All subjects with cardiac implanted electronic device (CIED) who are candidates of non-cardio-thoracic surgery or endoscopy and anticipated use of electrocautery

Exclusion Criteria:

* Recent CIED implantation (less than 6 weeks)
* Subjects with ICD who are pacemaker dependent
* Cardio - thoracic surgery
* Surgery over the CIED site
* Surgery site that preclude use of magnet in efficient way
* Subjects with Implanted unipolar leads

Primary outcomes:
measure: Any inappropriate sensing of EMI caused by electrocautery.
timeFrame: DURING SURGERY/PROCEDURE
Secondary outcomes:
measure: Any significant change in CIEDS parameters
timeFrame: WITHIN 1 DAY OF SURGERY/PROCEDURE
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam Medical Center
Study officials:
References:
citation: Crossley GH, Poole JE, Rozner MA, Asirvatham SJ, Cheng A, Chung MK, Ferguson TB Jr, Gallagher JD, Gold MR, Hoyt RH, Irefin S, Kusumoto FM, Moorman LP, Thompson A. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm. 2011 Jul;8(7):1114-54. doi: 10.1016/j.hrthm.2010.12.023. No abstract available.
Clinical trial NCT00013338: Supported Treadmill Ambulation Training After Spinal Cord Injury
Official title: Supported Treadmill Ambulation Training After Spinal Cord Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Spinal Cord Injury
Keywords: Spinal cord injury, ambulation, treadmill
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-03-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: This is a randomized, controlled trial to compare supported treadmill ambulation training (STAT) to conventional gait training for improving gait speed, gait endurance, gait efficiency and muscle function in SCI subjects injured more than six months prior to start of training. Each subject will receive twelve weeks of either CGT or STAT, given as 20 minutes of training within a one-hour period per day, five days per week. These subjects will be studied baseline, 4,8 and 12 weeks of training, and three months after the end of training with a battery of tests designed to evaluate the subjects' gait and muscle function.


Eligibility criteria: Spinal cord injury

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: VAMC, Houston
state: Texas
Study officials:
affiliation: Program Analysis and Review Section (PARS), Department of Veterans Affairs, Rehabilitation Research and Development Service
name: John Fryer, Ph.D. Asst. Director
affiliation: Program Analysis and Review Section (PARS), Department of Veterans Affairs, Rehabilitation Research and Development Service
name: Nancy Rocheleau, Program Analyst
References:
Clinical trial NCT00330538: Osteoporosis in Children With ALL
Official title: Incidence of Osteoporosis in Children With Acute Lymphoblastic Leukemia Undergoing Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Leukemia, Lymphocytic, Acute, L1
Keywords: Osteoporosis
Childhood acute lymphoblastic leukemia
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
First posted: 2006-05-29
Enrollment: 20
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Hypothesis:

Pediatric patients with acute lymphoblastic leukemia, treated with chronic glucocorticoids as a part of the leukemia treatment protocol, will have an increased incidence and severity of osteoporosis.

Detailed description: Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue. Osteoporosis is a devastating disorder with significant physical, psychosocial and financial consequences. Intensive chemotherapy and radiotherapy have led to significant improvements in long term, disease-free survival of children with malignancies. Unfortunately, there are many deleterious side effects associated with this therapy. Little is known about the longitudinal changes in bone mass accumulation and bone metabolism in these patients.

The purpose of this study is to evaluate the timing and severity of changes in bone mineral metabolism for children treated for childhood leukemia. Data will be used to establish treatment protocols with the goal of preventing severe fractures and pain in the acute treatment stage and severe osteoporosis and related pathology in the chronic stage.

Eligibility criteria: Inclusion Criteria:

* All pediatric patients with a new diagnosis of ALL between ages 4-18
* Patients who are expected to receive glucocorticoids as part of the leukemia treatment protocol
* Bone density measurements must be performed at the diagnosis visit or maximally within 48 hours after the first dose of glucocorticoids

Exclusion Criteria:

* Patients under 4 years of age are excluded due to lack of age appropriate standards for bone mineral density
* Glucocorticoid therapy of at least one month or longer within the six months prior to DX
* History of connective tissue or musculoskeletal disorders
* Biphosphonate therapy within the past 6 months
* Acute renal failure
* Serum creatinine equal to or higher than 4.5mg/dl
* Positive serum pregnancy test in adolescent females

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Children's Mercy Hospital
state: Missouri
Study officials:
affiliation: Children's Mercy Hospital Kansas City
name: Jadranka Popovic, MD
role: PRINCIPAL_INVESTIGATOR
References: